At its Sept. 14, 2026 interim results briefing, Junshi Biosc
文 / 小金
2026-09-14 13:30:03
来源:亚金网
At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types; Junshi plans to start Phase III for JS207 in 2026.
